NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) — Reportlinker.com Announces the Release of the Global Urolithiasis Management Devices Industry Report – https://www.reportlinker.com/p06033203/?utm_source=GNW
3 billion by 2027, with a CAGR of 5.5% over the analysis period 2020-2027. Extracorporeal Shock Wave Lithotripsy (ESWL), one of the segments analyzed in the report, is expected to register a CAGR of 5.3% and reach $926.3 million by the end of the analysis period. Taking into account the ongoing post-pandemic recovery, growth in the Intracorporeal Lithotripsy segment is adjusted to a revised CAGR of 5.9% for the next 7 years.
The US market is valued at US$434.5 million while China is forecast to grow at 8.8% CAGR
The U.S. urolithiasis treatment devices market is valued at US$434.5 million in 2020. China, the second largest economy in the world, is forecast to reach a projected market size of US$481.6 million by the year 2027, representing a CAGR of 8.7% over the 2020-2027 analysis period. Among the other notable geographic markets include Japan and Canada, which are forecasting growth of 3.3% and 4.5%, respectively, over the period 2020-2027. Within Europe, growth of approx. 4% CAGR is forecast for Germany. Led by countries like Australia, India and South Korea, the Asia-Pacific market is expected to reach US$311.3 million by 2027.
Percutaneous nephrolithotomy segment with 5.6% CAGR
In the global Percutaneous Nephrolithotomy segment…
